Clinical Trial News and Research

RSS

Amorcyte reports AMR-001 phase I trial results in heart attack patients

The American Heart Journal today reported results of a clinical trial evaluating Amorcyte, lead product candidate, AMR-001 for the treatment of damaged heart muscle following acute myocardial infarction.

22 Dec 2010

El Camino announces first patient implant in Medtronic CoreValve clinical trial

El Camino Hospital today announced its first patient implant in the Medtronic CoreValve® U.S. Clinical Trial.

22 Dec 2010

Echinacea only offers modest benefit in common cold: study

In a large clinical trial involving more than 700 adults and children researchers showed that the popular herbal remedy Echinacea can cut only half a day from a week long common cold. Echinacea has been marketed for a long time for the common cold. Echinacea, also known as purple coneflower has been shown to have benefits in some earlier studies while some show no benefits.

21 Dec 2010

Biovest issues FAQ update on BiovaxID personalized cancer vaccine

Biovest International, Inc. today issued the following update in the form of a "Frequently Asked Questions" report in response to the high volume of inquiries received following the Company's recent presentation at the 2010 American Society of Hematology Annual Meeting (ASH 2010) in Orlando, Florida.

21 Dec 2010

Study aims to deliver safer bone marrow transplant treatment strategy in patients with multiple myeloma cancer

A national clinical trial, which opens imminently, will aim to assess the impact of a novel anti-cancer drug in the setting of donor bone marrow transplantation for myeloma.

21 Dec 2010

Emisphere, Novo Nordisk partner to develop and commercialize oral formulations of insulins

Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial.

21 Dec 2010

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Genzyme Corporation today provided an extensive briefing on the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York.

21 Dec 2010

Use of metaphors may help doctors to recruit low-income people for cancer clinical trials

The language that doctors use with low-income, rural patients can help determine whether these patients agree to participate in clinical trials testing new cancer treatments, a new study found.

21 Dec 2010

Biomet Biologics completes enrollment in Recover Kit clinical trial for chronic tennis elbow

Biomet, Inc., a global leader in the manufacture of orthopedic and biotechnology products, announced today that its subsidiary, Biomet Biologics, LLC, has completed the required 230 subject enrollment for its Recover® Kit clinical trial. This clinical trial studies the use of the Recover® Kit device, which produces autologous platelet-rich plasma (PRP) to treat chronic tennis elbow (lateral epicondylitis).

21 Dec 2010

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.

21 Dec 2010

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Idera Pharmaceuticals, Inc. announced today preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. In the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment.

20 Dec 2010

EMA grants SME designation to PROLOR Biotech

PROLOR Biotech, Inc.,, a clinical stage company developing next generation biobetter therapeutic proteins, today announced that the European Commission and the European Medicines Agency (EMA) has granted PROLOR the designation of "Small and Medium Sized Enterprise" (SME).

20 Dec 2010

Arrowhead launches new company, Ablaris to commercialize novel weight loss technology

Arrowhead Research Corporation today announced that it has executed an exclusive world-wide license on technology developed by Drs. Wadih Arap and Renata Pasqualini at MD Anderson Cancer Center for use in weight loss and obesity-related metabolic conditions, and that it has launched a new company, Ablaris Therapeutics Inc., to commercialize this platform.

20 Dec 2010

Exciting progress made in MS research during 2010

Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS. Progress was also made toward finding ways to restore function and improving quality of life and specific MS symptoms through exercise, meditation, rehabilitation and medications, including the first therapy specifically approved to treat a symptom of MS (Ampyra).

20 Dec 2010

Cardio3 BioSciences presents positive C3BS-GQR-1 results in patients with acute myocardial infarction

Cardio3 BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces positive pre-clinical results from its in-house product candidate C3BS-GQR-1, to treat patients suffering from acute myocardial infarction in order to protect cardiac tissue from damage and direct heart stem cells to mature and restore pump function.

20 Dec 2010

Inspire's denufosol tetrasodium TIGER-1 Phase 3 trial for CF published in AJRCCM

Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.

20 Dec 2010

4SC AG's Phase IIb study evaluates efficacy of vidofludimus in RA patients

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today reported that it has completed enrolment of its COMPONENT Phase IIb study with vidofludimus, an oral inhibitor of IL-17 release, in rheumatoid arthritis (RA) patients. Data from the trial are expected to be announced in Q2 2011.

20 Dec 2010

RXi's dermal anti-scarring candidate selected to advance into development

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced the selection of its first RNAi therapeutic product candidate to advance into development.

20 Dec 2010

CF patients with normal to mildly impaired lung function may benefit from new investigational drug

Cystic fibrosis patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug.

19 Dec 2010

BioClinica board authorizes $2.0 million share repurchase program

BioClinica®, Inc.,, a global provider of clinical trial management services, announced that its Board of Directors has authorized a share repurchase program of up to $2.0 million of the Company's common stock over the next 18 months.

From Clario 17 Dec 2010

Clinical Trial News and Research

Amorcyte reports AMR-001 phase I trial results in heart attack patients

El Camino announces first patient implant in Medtronic CoreValve clinical trial

Echinacea only offers modest benefit in common cold: study

Biovest issues FAQ update on BiovaxID personalized cancer vaccine

Study aims to deliver safer bone marrow transplant treatment strategy in patients with multiple myeloma cancer

Emisphere, Novo Nordisk partner to develop and commercialize oral formulations of insulins

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Use of metaphors may help doctors to recruit low-income people for cancer clinical trials

Biomet Biologics completes enrollment in Recover Kit clinical trial for chronic tennis elbow

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

EMA grants SME designation to PROLOR Biotech

Arrowhead launches new company, Ablaris to commercialize novel weight loss technology

Exciting progress made in MS research during 2010

Cardio3 BioSciences presents positive C3BS-GQR-1 results in patients with acute myocardial infarction

Inspire's denufosol tetrasodium TIGER-1 Phase 3 trial for CF published in AJRCCM

4SC AG's Phase IIb study evaluates efficacy of vidofludimus in RA patients

RXi's dermal anti-scarring candidate selected to advance into development

CF patients with normal to mildly impaired lung function may benefit from new investigational drug

BioClinica board authorizes $2.0 million share repurchase program

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News